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Acentral pathological hallmark of Parkinson’s disease (PD) is thepresenceof proteinaceousdepositions known
as Lewy bodies, which consist largely of the protein a-synuclein (aSyn). Mutations, multiplications and poly-
morphisms in the gene encoding aSyn are associated with familial forms of PD and susceptibility to idiopathic
PD. Alterations in aSyn impair neuronal vesicle formation/transport, and likely contribute to PD pathogenesis by
neuronaldysfunctionanddegeneration.aSyn is functionallyassociatedwithseveralRabfamilyGTPases,which
perform various roles in vesicle trafficking. Here, we explore the role of the endosomal recycling factor Rab11 in
the pathogenesis of PD using Drosophila models of aSyn toxicity. We find that aSyn induces synaptic potenti-
ation at the larval neuromuscular junction by increasing synaptic vesicle (SV) size, and that these alterations are
reversed by Rab11 overexpression. Furthermore, Rab11 decreases aSyn aggregation and ameliorates several
aSyn-dependent phenotypes in both larvae and adult fruit flies, including locomotor activity, degeneration of
dopaminergic neurons and shortened lifespan. This work emphasizes the importance of Rab11 in the modula-
tion of SV size and consequent enhancement of synaptic function. Our results suggest that targeting Rab11
activity could have a therapeutic value in PD.
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disorder and affects 4% of the population over 80
years of age (1,2). Neuropathologically, this disorder is charac-
terized by the presence of Lewy bodies (LBs) and Lewy neurites
in dopaminergic neurons located in the substantia nigra pars
compacta, and the loss of neurons in this region (3). The main
protein component of LBs isa-synuclein (aSyn) (4). Point muta-
tions and multiplications in the gene encoding aSyn lead to auto-
somal dominant versions of PD. In addition, genome-wide
association studies suggest that polymorphisms in this gene in-
crease susceptibility to sporadic forms of this disease (5).
Although the precise cellular role of aSyn is still ambiguous,
aSyn is located at the pre-synaptic termini (6) and has been
implicated in modulating neurotransmitter release (7). More-
over, in pathological conditions, aSyn has been suggested to
cause defects in several vesicle trafficking pathways (8).
Rab proteins are highly conserved small GTPases that orches-
trate vesicle trafficking within a cell—with vesicle formation,
movement, tethering and targeting controlled by specific Rabs
(9). These proteins fluctuate between their target membranes
and the cytosol dependent on their GTP-bound (active) or
GDP-bound (inactive) status (10). Mutations in Rab genes
have been associated with diverse neurological diseases (11).
aSyn has been found to interact with several Rabs (12). Further-
more, aSyn disease-related pathology in model systems such as
impaired endoplasmic reticulum (ER)–Golgi vesicle trafficking
and loss of dopaminergic neurons is reversed by the overexpres-
sion of several Rabs, including Rab1, Rab3A and Rab8A
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(13–15). On the other hand, Rab11 has not been previously
implicated in PD, although it has been linked to other neurode-
generative disorders (16–18). Rab11 is involved in the traffick-
ing of vesicles between the recycling endosome and plasma
membrane (19) and the trans-Golgi network (20). Rab11 also
sequesters plasma membrane receptors and directs them to the
recycling pathway, which plays a role in cell migration (21)
and long-term potentiation (22).
The importance of Rab11 in the context of neurodegenerative
disorders is emphasized by studies of Huntington’s (HD) and
Alzheimer’s (AD) diseases. Indeed, Rab11 is functionally per-
turbed in several models of HD (23–26), and inhibition of
Rab11 activity impairs vesicle formation from recycling endo-
somes in HD patient fibroblasts (24). Rab11 abrogates loss
of dendritic spines in a primary neuronal model of HD, suggest-
ing that Rab11 may play a critical early role in the synaptic dys-
function observed in HD (26). Rab11 overexpression also
ameliorates synaptic dysfunction and neurodegeneration in a
Drosophilamodel of HD (26,27). Regarding AD, direct interac-
tions between Rab11 and the hydrophobic loops of presenilin 1
and 2 have been observed (28). Furthermore, oestrogen treat-
ment has been found to divert Rab11 to the trans-Golgi
network, thereby decreasingb-amyloid (Ab) generation by pro-
moting the budding of amyloid precursor protein-containing
vesicles (29), while blockage of Ab trafficking through Rab11
recycling vesicles enhances cellular Ab accumulation (30).
Due to these many links between Rab11 and neurodegenera-
tive disease, we hypothesized that Rab11 could play a role in
modulation of PD pathogenesis. Here, we employ Drosophila
melanogaster models of aSyn toxicity—and a panel of electro-
physiological, immunohistochemical, genetic and behavioural
analyses—to investigate the mechanistic role and therapeutic
potential of Rab11 in PD. In a related recent study, we also
demonstrated that Rab11 interacts with and modulates aSyn
aggregation and secretion (31).
RESULTS
Rab11 normalizes aSyn-dependent potentiation of synaptic
transmission at the Drosophila larval neuromuscular
junction
Expression of aSyn in flies yields several PD-relevant pheno-
types, including formation of LBs, dopaminergic neuron loss
and locomotor impairments (32). Here, we employed the
GAL4/UAS system (33) to drive aSyn expression in specific
tissues using two independent fly models carrying UAS-aSyn
transgenes [Model 1 from (34) and Model 2 from (35); see Mate-
rials and Methods]. As we previously established that aSyn oli-
gomers enhance basal synaptic transmission in rat hippocampal
slices (36), we assessed whether the electrophysiological
parameters of the neuromuscular junction (NMJ) in
aSyn-expressing larvae mirrored these effects. Indeed, pan-
neuronal expression of aSyn via the elavGAL4 driver (elav.
aSyn) in Model 1 strongly increased miniature excitatory junc-
tion potential (EJP) amplitudes (mEJP) from 1.17+ 0.05 to
1.45+ 0.09 mV (P , 0.05; Fig. 1A), with a similar pattern
observed in Model 2, though this failed to reach statistical signifi-
cance using ANOVA (Fig. 1B). More subtle effects on mEJP
amplitudes in both models became apparent when analyzing
mEJP distributions with the more sensitive Kolmogorov–
Smirnov test (KS test; Fig. 1C and D; Model 1—UAS versus
aSyn D ¼ 0.2783, P, 0.0001; Model 2—LacZ versus aSyn
D ¼ 0.1478, P, 0.0001). Notably, co-expression of Rab11
with aSyn normalized these electrophysiological changes in
both models and returned the mEJP amplitudes/distributions
back to control values [(Fig. 1A; Model 1—P , 0.01,
ANOVA) and (Fig. 1C and D; Model 1—aSyn versus
Rab11 + aSyn D ¼ 0.2729, P , 0.0001; Model 2—aSyn
versus Rab11 + aSyn D ¼ 0.2264, P , 0.0001, KS test)].
We also assessed evoked EJPs (eEJPs) with aSyn expression
in these lines, and noted robust potentiation in Model 2 (P ,
0.01; Fig. 1F). Model 1 larvae, on the other hand, exhibited no
changes in eEJPs (Fig. 1E). We next analyzed the quantal
content (QC) and found that QC was specifically increased in
Model 2 flies, providing a rationale for the larger eEJPs observed
(P , 0.05, Fig. 1F). Co-expression of Rab11 with aSyn led to a
reduction and normalization of eEJP amplitudes and QC in these
animals (P , 0.001 and ,0.05, respectively; Fig. 1F), reiterat-
ing a modulatory role of Rab11 in aSyn-dependent potentiation
of synaptic transmission.
Rab11 ameliorates aSyn synaptic defects by restoration of
synaptic vesicle size
To investigate the mechanism(s) underlying Rab11 modulation
of aSyn-induced electrophysiological abnormalities at the NMJ,
we next explored localization of Rab11 and aSyn in larval NMJs
using immunocytochemistry. We found endogenous Rab11 to
be highly expressed in segmental axonal termini, synaptic
boutons and muscle tissues (Supplementary Material, Fig. S1A).
Model 1 flies, elav.aSyn, exhibited robust aSyn levels at the
NMJ (Fig. 2A). Significant co-localization between aSyn and
cysteine-string protein (CSP)—an endogenous marker of synaptic
vesicles (SVs) (37)—was observed in both bouton types (1s
and 1b) found at the Drosophila NMJ [Fig. 2B, Pearson’s
coefficient ¼ 0.852, intensity correlation quotient (ICQ) ¼
0.353]. Furthermore, using immunocytochemistry, we found
aSyn enrichment in elav.aSyn expressing NMJs co-stained
with the active zone containing scaffolding protein, bruchpilot
(BRP) (38) (Supplementary Material, Fig. S1B). These data
suggest that aSyn is associated with SVs and is localized to the
Figure1.Rab11 reverses aSyn-dependent increases in average mEJP and eEJP amplitudes. Representative mEJP trace and summary graphs of averaged mEJP ampli-
tudes for both Model 1 (A) and Model 2 (B) aSyn transgenic lines and their respective controls in third instar wandering larvae. Pan-neuronal expression of aSyn
via the elavGAL4 driver in Model 1 induced a strong increase in mEJPs in aSyn animals. Co-expression of Rab11 with aSyn returned the amplitudes back to
control values (N ¼ 8–19). No change was observed in Model 2 (elavGAL4 driver) animals (N ¼ 8–13). Relative cumulative frequency histograms and cumulative
frequency curves for the mEJP amplitudes for both Model 1 (C) and Model 2 (D) aSyn transgenic lines and their respective controls are shown. eEJP sample recordings,
summary graphs of averaged eEJP amplitudes and QC for Model 1 (E) and Model 2 (F) aSyn transgenic lines corrected for non-linear summation, which takes
into account any changes in resting membrane potential. Pan-neuronal expression of aSyn via the elavGAL4 driver in Model 2 aSyn animals induced an increase
in eEJPs and QC (F; N ¼ 6–13). Co-expression of Rab11 with aSyn led to a reduction and normalization of eEJP amplitudes in the wC31 animals. No change
was observed with Model 1 larvae regarding eEJP amplitudes or QC (E; N ¼ 5). Data are mean+SEM. ANOVA with Newman–Keuls post hoc tests.
∗P, 0.05, ∗∗P, 0.01 and ∗∗∗P , 0.001.
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Figure 2. aSyn localizes to CSP in larval NMJ boutons. (A) Representative third instar larval NMJs of aSyn and Rab11 + aSyn individuals (elavGAL4 driver with
Model 1 line) immunostained with aSyn and CSP antibodies. Scale bar ¼ 8 mm. (B) The spatial distribution of aSyn and CSP overlaps as indicated by Pearson’s and
ICQ coefficients. Mean+SEM. ANOVA with Newman–Keuls post hoc tests. ∗∗P , 0.01.
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synaptic active zones. In larvae overexpressing Rab11 we
observed similar localization patterns for these proteins, though
aSyn distribution appears to be shifted towards the membrane,
and away from the centre of the bouton (Fig. 2 and Supplementary
Material, Fig. S1B). A modest increase in overlap between aSyn
and CSP was also observed (Fig. 2B, Person’s coefficient ¼
0.916, ICQ¼ 0.396), indicating more aSyn is localized to SVs.
No difference in aSyn/BRP co-localizationwas observed (Supple-
mentary Material, Fig. S1B).
As these data suggest that localization of aSyn/Rab11 to SVs
may play an important role in modulating the observed electro-
physiological phenotypes, we next employed electron micros-
copy to determine SV size at the larval NMJ (Fig. 3A and B).
Of the two bouton types found at the NMJ in fruit flies, 1s
boutons display larger SVs, contain fewer mitochondria and
active zones, and exhibit less enveloping subsynaptic reticulum
(39). Notably, 1s boutons are proposed to play the major role in
generation of synaptic activity in response to stimuli at the larval
NMJ (39). SV diameters of both bouton types were determined in
larvae expressing aSyn pan-neuronally, as well as in transgene
controls. We observed a significant increase in SV diameters
in 1b and 1s boutons in both transgenic lines expressing aSyn
compared with the UAS controls (P, 0.001; Fig. 3C–H and
Supplementary Material, Fig. S2), leading to a right shift in
cumulative probability plots for SV size distribution (Fig. 3E
and F, and Supplementary Material, Fig. S2C and D). The
increased quantal responses at the larval NMJ due to aSyn
could thus be explained by increased SV size. Notably, overex-
pression of Rab11 restored vesicle size in aSyn larvae (P,
0.001; Fig. 3C–H and Supplementary Material, Fig. S2), indi-
cating that increased levels of Rab11 normalize SV size and
thereby ameliorate the altered synaptic transmission due to aSyn.
Rab11 ameliorates aSyn-dependent larval crawling
impairments
Third instar larvae display characteristic crawling behaviour com-
prising forward movements in a specific direction followed by
pauses during which the surrounding area is sensed (40). We
have previously observed defects in this crawling behaviour due
to aSyn expression (15), and thus here employed this metric to
monitor if the Rab11-dependent improvements in synaptic trans-
mission at the NMJ led to consequent amelioration of locomotor
impairments in larvae. Expression of aSyn in motor neurons
using the c164GAL4 driver (41) resulted in reduced distance trav-
elled during a 2-min period relative to controls (P, 0.001;
Fig. 4A, B and D). Strikingly, when Rab11 was co-expressed
in aSyn larvae, crawling distance returned to control levels
(P, 0.001; Fig. 4A, B and D). Larvae expressing aSyn in dopa-
minergic neurons (using the pleGAL4 driver) also exhibited
reduced crawling distance (P, 0.001; Fig. 4C and E), which
was reversed by Rab11 co-expression (P, 0.001; Fig. 4C and E).
To further explore whether active Rab11 is required for
the protection observed above, we also investigated the effect
of the GDP-bound, dominant-negative Rab11 mutant (Rab11
S25N) (42) on the crawling behaviour of aSyn animals. We
found that Rab11S25N expression did not rescue aSyn-
dependent crawling defects (P ¼ ns, Supplementary Material,
Fig. S3A), and indeed, in wild type (WT), larvae caused a
significant reduction in the distance crawled (P, 0.001;
Supplementary Material, Fig. S3A). These data support the
notion that active Rab11 is required for protection in aSyn flies.
Rab11 reverses the loss of dopaminergic neurons in adult
Drosophila brains
Having found that Rab11 ameliorates PD-relevant phenotypes
during development, we next sought to extend these findings
into adult flies. Previous studies have shown that expression
of aSyn causes the degeneration of tyrosine hydroxylase
(TH)-expressing dopaminergic neurons in aged adult flies
(34,43). We thus analyzed the protocerebral posterior inferior-
lateral (PPL1) subset of TH neurons located in the adult Dros-
ophila posterior brain, which is particularly sensitive to aSyn
expression (Fig. 5A) (15). We found that pan-neuronal expres-
sion of aSyn led to loss of these neurons (P, 0.001; Fig. 5B
and Supplementary Material, Fig. S4A), which was reversed
by overexpression of Rab11 (P , 0.001; Fig. 5B and Supple-
mentary Material, Fig. S4A). Similarly, a progressive loss
of dopaminergic neurons was observed when aSyn expres-
sion was limited to TH-positive neurons using the pleGAL4
driver, with 30-day-old flies displaying marked neuronal loss
(P , 0.001; Fig. 5C), which again was ameliorated upon
Rab11 co-expression (P, 0.001; Fig. 5C).
To support our immunocytochemical data, we employed a
luminescence-based assay in which luciferase was co-expressed
with aSyn as a further readout for neuronal dysfunction/death in
these flies. A reduction in luciferase signal was found in flies
expressing aSyn both pan-neuronally (P, 0.05, Supplementary
Material, Fig. S4B) and specifically in the TH-positive neurons
(P , 0.001, Fig. 5D). The overexpression of Rab11 in both con-
ditions increased the luciferase signal (P , 0.05 for both drivers;
Fig. 5D and Supplementary Material, Fig. S4B), indicating neur-
onal rescue. Taken together, these results suggest that increased
Rab11 expression protects dopaminergic neurons in the Dros-
ophila central nervous system from aSyn toxicity.
We next assessed whether Rab11 protects against aSyn-
dependent neurodegeneration more generally. For these experi-
ments, we drove expression of aSyn with the eye-specific
gmrGAL4 driver and evaluated degeneration of photoreceptor
neurons using the pseudopupil assay, a widely used readout in
several fly neurodegeneration models (34,44,45). We found
that aSyn expression led to a 62% reduction in rhabdomeres
in 30-day-old flies (P , 0.001, Fig. 5E), and that co-expression
of Rab11 restored rhabdomere number to approximately WT
levels (P , 0.001 versus aSyn; Fig. 5E). Thus, Rab11 is able
to generally reverse aSyn-dependent neurodegeneration, regard-
less of neuronal population targeted.
Finally, in order to elucidate potential protective mechanisms
underlying Rab11 protection, we assessed the level of soluble/
insoluble aSyn in adult heads at Day 30 post-eclosion as a
measure of aSyn aggregation. Importantly, we found that pan-
neuronal expression of Rab11 significantly decreased levels of
insoluble aSyn (P , 0.05, Fig. 5F).
Rab11 ameliorates disease-relevant phenotypes in adult flies
expressing aSyn
We next analyzed locomotor impairments due to pan-neuronal
and dopaminergic expression of aSyn by assessing negative
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Figure 3. Increased SV size in aSyn larvae is rescued by Rab11 overexpression. Representative images of 1b (A) and 1s (B) boutons from WT NMJs. Average
vesicle diameter in 1b (C) and 1s (D) boutons for UAS control, aSyn and Rab11 + aSyn larvae (Model 1 line). Increased vesicle size was observed upon expression
of aSyn, which is fully reversed to control levels by Rab11 overexpression. Relative cumulative frequency plots and histograms and of 1b (E andG) and 1s (F andH)
boutons; a right shift is observed in aSyn larvae in comparison with controls. SV size is rescued by overexpression of Rab11 in both boutons (1b boutons,N ¼ 2737–
3190 and 1s boutons, N ¼ 804–1019). Data are mean+SEM. ANOVA with Newman–Keuls post hoc tests. ∗∗∗P, 0.001.
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geotaxis (climbing) in aged flies (Fig. 6A and B, and Supplemen-
tary Material, Fig. S5), as locomotor activity is linked to dopa-
minergic neurons (46). We found that pan-neuronal expression
of aSyn led to a significant decrease in climbing relative to con-
trols at all post-eclosion ages tested (P , 0.001; Fig. 6A and B).
The overexpression of Rab11 rescued this impairment at all ages
(P , 0.001). A similar deficiency in climbing was displayed by
flies in which aSyn was selectively driven in dopaminergic
neurons, with a decrease in climbing observed at Day 20 and
30 (P , 0.001, Supplementary Material, Fig. S5), and an
improvement in behaviour observed upon overexpression
of Rab11. We also evaluated the climbing phenotypes of
Rab11S25N + aSyn flies, and found that overexpression of
Rab11 S25N significantly decreased climbing of aSyn flies
at all ages tested (P, 0.001; Supplementary Material, Fig. S6).
Finally, we assessed if Rab11 overexpression could amelior-
ate the shortened lifespan exhibited by aSyn flies. We found that
pan-neuronal Rab11 expression reversed the reduced survival
observed in both aSyn models (P, 0.001; Fig. 6C and D),
extending median lifespan from 70 to 79 days (Fig. 6C), and
from 48 to 68 days, respectively (Fig. 6D).
DISCUSSION
Although the exact function of aSyn is not fully understood,
some studies suggest that it is linked to synaptic transmission.
This is emphasized by its localization to pre-synaptic termini
(47) and its involvement in several steps of the neurotransmis-
sion machinery. The overexpression of aSyn in murine
Figure4.Rab11 overexpression rescues impaired locomotor behaviour in third instar larvae expressing aSyn. Representative crawling behaviour of control and larvae
expressing aSyn, and Rab11 + aSyn in the motorneurons (A). Mean distance travelled by Model 1 larvae expressing aSyn, GFP + aSyn and Rab11 + aSyn in the
motorneurons (B) and in the dopaminergic neurons (C). Similar crawling behaviour was observed in Model 2 larvae expressing aSyn in motorneurons (D) or dopa-
minergic neurons (E). Data are mean+SEM. ANOVA with Newman–Keuls post hoc tests. ∗∗∗P, 0.001. N ¼ 30.
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dopaminergic neurons leads to inhibition of TH activity with a
consequent reduction in dopamine synthesis (48,49). Moreover,
aSyn association with the distal reserve pool of SVs and the
SNARE complex indicate a physiological role of aSyn in the
recycling of SVs and their fusion with the plasma membrane
(6,50). aSyn has also been found to interact with several Rab
GTPase proteins, which are highly conserved regulators of intra-
cellular membrane trafficking between organelles (9). aSyn
associates with Rab3a, Rab5 and Rab8 in dementia with LB
patients and mouse models (12,51), and an interaction between
endocytosed aSyn and Rab11a has been observed in mammalian
cells (52). Notably, Rab1 and Rab8a overexpression reverses
aSyn-dependent impairment of ER–Golgi transport in yeast,
fruit flies and Caenorhabditis elegans (13–15).
Synaptic dysfunction occurs in several human neurodegen-
erative diseases prior to neuronal loss and the manifestation of
deficient behaviours (53). For this reason, we first investigated
the effect of aSyn toxicity in Drosophila larvae. We found that
synaptic transmission was altered at the NMJ, and that this cor-
related with an enlargement of SVs. These physiological effects
had a negative consequence on larval crawling behaviour when
aSyn was expressed either in the motorneurons or in the dopa-
minergic neurons. Locomotor dysfunction was maintained
through to adults, as evidenced by decreased climbing at all post-
eclosion ages tested. Finally, the survival of flies expressing pan-
neuronal aSyn was diminished compared with the controls.
Strikingly, for all these aSyn-mediated abnormalities, overex-
pression of Drosophila Rab11 significantly ameliorated these
mutant phenotypes.
We recently demonstrated that Rab11 similarly rectifies
several phenotypes in a fruit fly model of HD, including compro-
mised spontaneous miniature and evoked transmission and SV
size (27), although these effects were in the inverse direction
to those observed in the current study with aSyn flies. The
ability of Rab11 to normalize SV size in both experimental para-
digms indicates that it plays a critical role in homeostasis of SV
size. Indeed, several Rab (-interacting) proteins have been sug-
gested to act as mediators of synaptic homeostasis (54,55). Sup-
porting our observations here, aSyn overexpression in primary
mouse neurons causes an enlargement in SVs (56). We further
found that the increased amplitude of miniature events corre-
lated with larger SV diameters.
How does aSyn expression lead to SV enlargement? A pos-
sible explanation can be found in the propensity of aSyn to
interact with Rab5 (57). Rab5 plays a key role preventing the
fusion of SVs with each other—known as homotypic fusions
(57). Therefore, by sequestering or negatively interacting
with Rab5, aSyn may lead to increased fusion between SVs
resulting in their enlargement (Fig. 7). Alternatively, aSyn
may function as a scaffold protein attracting and promoting
the fusion between multiple vesicles. This is in agreement
with the observation that the expression of aSyn in yeast
causes vesicle accumulation (58). aSyn has also been shown
to interact with clathrin signalling (59,60) and clathrin together
with its adaptor proteins is involved in regulating vesicular size.
This could point towards a possible regulation of synaptic
transmission via aSyn. The possibility that the aSyn-dependent
increases of SVs, miniature events and evoked release occur by
promoting the assembly of the SNARE complex, with its role in
fusion mechanisms with the plasma membrane (50), should
also be considered.
Interestingly, we observed differences in eEJPs between aSyn
models—while Model 2 aSyn larvae exhibited potentiation of
these amplitudes, Model 1 larvae displayed no change. This
could be a consequence of homeostatic and compensatory down-
regulation of evoked transmission in response to the greater
miniature events observed in the Model 1 aSyn animals.
Similar mechanisms of homeostasis have been shown as an upre-
gulation of QC following genetic or pharmacological reduction
in postsynaptic quantal responses (61,62).
It is clear from our work that aSyn perturbs—and that simul-
taneous Rab11 overexpression restores—vesicle trafficking. In
this regard, Rab3—a GTPase localized to SVs—has been impli-
cated in synaptic homeostasis (54). Given the ubiquitous expres-
sion of Rab11 and its localization to synaptic boutons (63), it is
possible that Rab11 performs a similar function at the synapse.
In this scenario, aSyn would perturb the fine balance in synaptic
transmission by interfering directly with Rab11 or with some
effectors that regulate its function (Fig. 7). The overexpression
of Rab11 would thereby compensate this dysfunction, shifting
the system to a more ‘normal’ state. Recent work indicates that
aSyn interacts with the GTP/GDP-binding pocket of Rab8a,
abrogating its function (15). It is thus possible that aSyn may
have a similar negative impact on the inactive–active state of
Rab11. Enhanced Rab11 activity could also modulate the endo-
somal recycling rate in aSyn flies and thereby alter delivery of
vesicle-required proteins to the membrane. Notably, Rab11
has been shown to interact with the 1 subunit of the vacuolar
type H+-ATPase (64), and a possible enhanced interaction
with the vesicular H+-ATPase could alter vesicular parameters
and rescue aSyn-dependent defects.
aSyn present in vesicles has an increased propensity to aggre-
gate compared with its cytosolic counterpart (65). Thus, aSyn
inclusion formation due to accumulation of defective vesicles
may serve as an initial signal for enhancing further aggrega-
tion processes. This aSyn cluster may then sequester several
Figure5.Dopaminergic neuron loss is reversed by Rab11 overexpression. Representative adult (Day 30)Drosophilaposterior inferiorlateral protocerebrum confocal
images (PPL1, circled) of control (left panel) and Model 1 flies expressing GFP + aSyn (middle panel) or Rab11 + aSyn (right panel), driven by elavGAL4 and immu-
nostained with anti-TH antibody. Scale bar ¼ 40 mm. (A) Numbers of PPL1 neurons in flies at Day 1 and Day 30 (elavGAL4 inB andpleGAL4 inC). The expression of
aSyn and GFP + aSyn by both drivers decreases the number of PPL1 cells, which is restored to normal levels by the overexpression of Rab11 (N ¼ 19–65 hemi-
spheres). Luciferase intensity measurement in Model 1 flies expressing aSyn in dopaminergic neurons (D). The reduction in luciferase signal is restored by the over-
expression of Rab11 (N ¼ 4). Quantification of average rhabdomeres per ommatidum in aSyn flies with and without photoreceptor Rab11 overexpression at Day 30
(E). Expression of aSyn via gmrGAL4 leads to a reduction in the number of photoreceptors in Model 1 flies, whereas Rab11 overexpression prevents this neurode-
generation (N ¼ 60–136 ommatidia). (F) aSyn levels in elav-driven aSyn and Rab11 + aSyn fly heads. Representative immunoblot of aSyn soluble and insoluble
fractions (left panel). The graphs represent immunoblot quantification of aSyn in the soluble (middle panel) and insoluble (right panel) fractions. The overexpression
of Rab11 reduces the level of aSyn in the insoluble fraction, whereas no changes are found in the soluble fraction (N ¼ 4). Data are mean+SEM. ANOVA with
Newman–Keuls post hoc tests. ∗P , 0.05, ∗∗∗P, 0.001 and ns ¼ not significant.
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proteins—including Rab11—depleting cellular factors involved
in the diverse physiological processes. Interaction between aSyn
and Rab11 has been demonstrated in parallel work conducted in
a human cell model of PD by co-immunoprecipitation and
co-localization studies (31). Importantly, Rab11 expression
was found to decrease the number of aSyn inclusions and cellular
toxicity, likely due to enhanced aSyn secretion from the cells
(Fig. 7), which may explain the alterations in aSyn localization
observed at the larval NMJ due to Rab11 overexpression. Our
results from aged Drosophila heads support this role for Rab11
in the clearance of toxic insoluble aSyn, and further show that
its protective properties depends on its activity, as the Rab11
dominant-negative variant failed to rescue any of the phenotypes
assessed. Although the mechanisms are not fully understood,
aSyn can actively be secreted from neurons via the endocytic
pathway, exosomes and the ER/Golgi-to-plasma membrane
secretory pathway (65,66).
This study shows for the first time that Rab11 can modulate
aSyn-dependent synaptic dysfunction and neurodegeneration.
We have found that Rab11 robustly ameliorates PD-related phe-
notypes induced by aSyn overexpression. Thus, small molecules
which increase Rab11 activity may have therapeutic relevance
for PD (67). Moreover, as Rab11 has been implicated in both
Huntington’s and Alzheimer’s diseases, such potential drug
strategies may have a general clinical value for neurodegenera-
tive diseases.
MATERIALS AND METHODS
Drosophila genetics
Fruit flies were maintained on standard maize food at 258C in a
light/dark cycle of 12 : 12. The elavGAL4 [c155], w;+; pleGAL4
(8848), w; UASRab11-GFP; + (8506), w; +; UASaSyn (8146),
w; UASeGFP;+ (5431) and yw; UASRab11-YFP-S25N; +
(23261) fly stocks were obtained from the Bloomington
Stock Center (Bloomington, Indiana). The UASluc line was
a gift from Norbert Perrimon (Harvard Medical School).
Figure6. aSyn-dependent adult phenotypes are ameliorated by Rab11 overexpression. Mean climbing pass rate for Model 1 (A) and Model 2 (B) flies expressing aSyn,
GFP + aSyn and Rab11 + aSyn pan-neuronally by theelavGAL4 (N ¼ 50–60 per condition). aSyn expressioncausesa reduction in climbing at all post-eclosionages,
which are strongly rescued by Rab11 overexpression. Lifespan was evaluated in Model 1 and Model 2 flies expressing aSyn pan-neuronally (C and D, respectively,
N ¼ 100 per genotype). aSyn expression increases mortality, which is reversed by Rab11 overexpression (P, 0.001 for both models). Data are mean+SEM.
ANOVA with Newman–Keuls post hoc tests. ∗∗P , 0.01, ∗∗∗P , 0.001 and ns ¼ not significant.
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The c164GAL4 driver line was a gift from Juan Botas (Baylor
College of Medicine). The UASlacZ and UASaSyn wC31 trans-
genic lines were kindly provided by Alf Herzig (Max-Planck-
Institut fu¨r Biophysikalische Chemie). We employed two
transgenic models for aSyn expression. The first model (Model
1) exploits a transgene encoding WT aSyn, which is inserted
randomly into the genome using P-element-based transgenesis
(34), whereas the second model (Model 2) harbours a transgene
encoding WT aSyn targeted to the attP landing site in the
3R-86Fb genomic region using the wC31-based site-specific
recombination system (35). Flies carrying UASlacZ targeted to
the same location were used as controls.
Behavioural assays
For larval crawling experiments, crosses were set up on standard
maize fruit fly food mixed with 0.05% Bromophenol Blue
(FisherBiotech) as described previously (27). Young, deep blue-
coloured third instar wandering larvae were used for the crawl-
ing assay. Each larva was washed in distilled water and placed
in the middle of a 145 mm petri dish where 0.8% agarose was
previously poured and set. The distance covered by the larva in
2 min was manually tracked on a transparent paper placed on
the top of the petri dish lid. The tracks were scanned and the dis-
tance calculated using ImageJ (68).
Figure 7. Model suggesting how aSyn may alter normal synaptic function of Rab GTPases. Left panel: normal synaptic transmission. Right panel: aSyn expression
causes an enlargement of SVs by sequestering Rab5, which is normally involved in preventing homotypic fusion between SVs. Alternatively, aSyn may function as a
scaffold protein attracting and promoting the fusion between multiple vesicles. Either mechanism could lead to an increase in synaptic transmission. aSyn interaction
with Rab11 reduces its activity and the vesicle trafficking associated with it. The overexpression of Rab11 reverses these defects, by reducing aSyn aggregation and
enhancing its secretion, therefore restoring normal vesicle trafficking.
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Negative geotaxis assays were performed as described (69).
Briefly, flies carrying the desired genotype were placed in a
cylinder consisting of two empty tubes taped together along
the centre (with a diameter of 2.3 cm and a total length of
18.4 cm). An 8 cm line was drawn from one end identifying
the threshold that flies must reach in order to pass. Before the ex-
periment, flies were left to acclimatize for 1 min. For each trial,
the tubes were tapped gently in order to send all the flies to the
bottom. The flies were then allowed to fly or scale the sides of
the tube for 10 s and the number of flies which passed the thresh-
old recorded. The same cohort of flies was retested 10 times. In
between climbing trials, the flies were allowed to rest for 1 min.
This process was repeated on Day 10, 20 and 30 post-eclosion.
For longevity, females carrying the desired genotype were
collected and kept in groups of 10 in separate vials. Vials were
inspected and changed every 2–3 days, and the number of flies
remaining alive was scored.
Electrophysiology
Current clamp recordings using sharp electrodes [using pClamp
10, an Axoclamp 700B amplifier and Digidata 1321A (Molecu-
lar Devices, USA)] were made from ventral longitudinal muscle
6 in abdominal segments 2 and 3 of third instar wandering larvae
in haemolymph-like (HL-3) solution containing 1.5 mM Ca2+ as
described previously (70). Recording electrodes (10–20 MV)
were filled with 3 M KCl. All eEJP/mEJPs were recorded from
muscles with resting potentials more negative than 260 mV
and at 228C as differences in recording temperature cause
changes in glutamate receptor kinetics and amplitudes (71).
All eEJP amplitudes were corrected for non-linear summa-
tion (72). Larval rearing temperatures were 258C to avoid
temperature-dependent fluctuations of NMJ morphology and
evoked responses (73). QC was calculated by dividing the
mean eEJP amplitudes by the mean mEJP amplitude of a given
cell. mEJPs and eEJPs were low-pass filtered at 1 kHz. Data
were collected from averaged multiple eEJPs and 60 s of
mEJP recordings per muscle.
Determination of SV size
Preparation of NMJ tissues for electron microscope imaging was
performed as previously described (27). About 1000 SV dia-
meters were evaluated using the ImageJ software from four
larvae for each genotype and analyzing at least six independent
boutons per animal.
Immunocytochemistry
For larval immunostaining, third instar larvae were dissected and
immunostained as described (74). Briefly, larvae were collected
and dissected in ice-cold 1× PBS before being fixed for 20 min
in 4% formaldehyde–PBS. Samples were washed twice for
15 min in 0.1% PBST (1× PBS + 0.1% Triton-X), followed
by 2× 30 min washes with 0.2% BSA in 0.1% PBST (PBTB)
and 2 × 15 min washes with 2% goat serum in PBTB (PBTN).
Samples were incubated overnight at 48C with primary antibody.
CSP (mouse, 1 : 100, Developmental Studies Hybridoma Bank),
nc-82 (mouse, 1 : 100, Developmental Studies Hybridoma
Bank), aSyn (rabbit, 1 : 100, Millipore) and HRP (rabbit, 1 :
100, Jackson ImmunoResearch) were used. Larvae were then
washed 2 × 15 min with PBTB and incubated for 30 min with
PBTN. Rabbit Cy2 and mouse Cy5 (1 : 200, Abcam) were
used as secondary antibodies and incubated at room temperature
for 2 h. Finally, samples were washed 2 × 15 min with PBTB
and mounted in 3% n-propylgallate + 80% glycerol PBS solu-
tion.
For immunocytochemistry of adult brains, 15 virgin females
were collected at a specific age and fixed overnight in 4%
formaldehyde–PBS. Brains were dissected in ice-cold PBS and
permeabilized via 3 × 20 minute washes with 1% PBST fol-
lowed by a wash in a blocking solution made of 10% goat
serum in 0.5% PBST for at least 1 h. Samples were incubated
with mouse TH antibody (1 : 100, Immunostar) overnight at
48C. Unbound antibody was removed by 3 × 20 min washes
in 0.5% PBST before being incubated for 2 h at room tempera-
ture with secondary antibody (Anti-mouse Cy5, 1 : 500). After
3 × 20 min washes with 0.5% PBST, brains were mounted in
3% n-propylgallate + 80% glycerol PBS solution.
Rhabdomere immunostaining was performed by removing fly
heads and fixing overnight at 48C in 4% formaldehyde–PBS.
Heads were washed 3 × 5 min in PBS prior to dissection. Eyes
were removed from the brain and washed 3 × 20 min in 1%
PBST (Triton-X). Samples were incubated for 30 min in 10%
goat serum in 0.5% PBST for at least 1 h followed by a 48C over-
night incubation with Alexa Fluorw 488 Phalloidin (1 : 200,
Molecular Probes). Eyes were then washed 3 × 20 min with
0.5% PBST and mounted in 3% n-propylgallate + 80% glycerol
PBS solution. All samples were visualized on an Olympus
FV1000 confocal microscope and processed with an Olympus
software.
Luciferase assays
Aged flies were collected in quadruplicate groups of 10 virgin
females and frozen in liquid nitrogen. Proteins were extracted
following manufacturer’s instructions (Luciferase Assay System,
Promega). Briefly, flies were placed in 200 ml of cell lysis buffer
and homogenized in a 1.5 ml microcentrifuge tube. Samples
were subsequently subjected to three cycles of freezing in dry ice
and thawing at 378C, followed by centrifugation at 9300 g for
10 min and collection of lysis supernatants. Protein concentrations
were determined by Bradford’s Reagent (Sigma-Aldrich) and used
for normalization. To quantify luciferase activity, 20 ml of each fly
sample was distributed in a 96-well plate and 100 ml of Luciferase
System reagent was injected in each. Luminescence was detected
using a Fluorostar Omega microplate reader (BMG Labtech).
Immunoblotting
Insoluble aSyn was prepared as described in ref. (75) with minor
modifications. Hundred heads of 30-day-old flies were collected
and homogenized using a sterile plastic pestle in TNE buffer
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl and 5 mM EDTA)
containing protease inhibitors (Complete Mini; Roche) and
detergents (0.5% Nonidet P-40). The homogenate was centri-
fuged (30 min at 100 000g at 48C), and the resulting pellet (P1)
and supernatant (S1, soluble) fractions were collected. The P1
was resuspended in the same TNE/NP-40 buffer followed by
centrifugation at 100 000 g for 1 h at 48C. The pellet was taken
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as the insoluble fraction and solubilized in TNE buffer con-
taining 1% SDS. S1 and P2 samples were quantified using
Bradford’s Reagent (Sigma-Aldrich) and normalized. Proteins
were loaded on SDS–PAGE gels, transferred onto nitrocellulose
membranes (Whatman), blocked in 5% powdered milk and incu-
batedwith the primaryantibody, eithermouse anti-aSyn(1 : 1000,
BD transduction Laboratories) or mouse anti-tubulin (1 : 10 000,
Sigma). Horseradish peroxidase-conjugated goat anti-mouse
(1 : 10 000; Vector Labs) was used as the secondary antibody
and signals were visualized using SuperSignalw West Dura
Extended duration Substrate (Thermo Scientific).
Statistical analysis
Statistical analysis was performed using Prism 6 (GraphPad
Software). In general, analysis was carried out using ANOVA
with the Newman–Keuls a posteriori test. mEJP amplitude dis-
tributions were analyzed using the KS test in Prism 6 (GraphPad
Software). For longevity, survival curves were generated and
data were analyzed using the Kaplan–Meier method and
log-rank statistics in Prism 6 (GraphPad Software).
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